CUPERTINO, Calif., Aug. 31, 2011 /PRNewswire via COMTEX/ —
DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.
- Jim Brown, President and CEO, will present at the Stifel Nicolaus Healthcare Conference in Boston on Thursday, September 8 at 3:50 p.m. Eastern Time. A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/stifel/healthcare2011/19213681.cfm.
- Matt Hogan, Chief Financial Officer, will present at the Rodman & Renshaw Life Sciences Conference in New York on Monday, September 12 at 10:40 a.m. Eastern Time. A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rrshq20/drrx .
- Matt Hogan will also present at the UBS Global Life Sciences Conference in New York on Monday, September 19 at 3:00 p.m. Eastern Time. A live audio webcast of the presentation will be available by accessing DURECT’s homepage at http://www.www.durect.com and clicking “Investor Relations.” If you are unable to participate during the live webcast, the call will be archived on DURECT’s website under Audio Archive in the “Investor Relations” section.
About DURECT Corporation
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR®, ELADUR(TM) and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation